PPG Experts to Showcase Future of Automotive Color Styling, Application Technology at Surcar Europe 2021
1.7.2021 16:02:00 EEST | Business Wire | Press release
PPG (NYSE: PPG) today announced that its experts will share the future of sustainable automotive color styling and application technology in presentations at the Surcar Europe 2021 automotive engineering and design show, which is being held this week in Cannes, France.
Sabine Griesbeck, PPG digital transformation technical manager, will discuss the future of color development using digital color styling. A presentation by Sven Reil, PPG automotive application manager, Europe, Middle East and Africa, will cover paint as an enabler for precision application. Both presentations will be given on July 1.
PPG’s digital styling program will enable automotive designers to execute exceptionally realistic three-dimensional modeling of automotive colors and effects on virtual car designs and surfaces, significantly speeding up the process of developing new colors and reducing waste.
“Prior to the development of PPG's digital color styling program, the time taken from the designer’s vision to a final color could be as long as nine months,” said Griesbeck. “The color team developed several different variations of a color. These are then applied to test panels that are sent to the customer for review. This generated waste, and having small panels does not give a good real-world representation of the color.”
PPG’s digital styling library features a proprietary “speed shape” that accurately depicts the interaction of color, geometry and light. It also offers the option to download digital color files that are fully compatible with industry-standard color-rendering software. This enables design teams to collaborate with PPG experts directly, remotely and in real time.
“This is the first step in fully digitizing the entire color styling process for PPG customers,” Griesbeck said. “Imagine if in the future you can adjust a color virtually according to your wishes, and the new color design is digitally born and ready to use in production. There are also significant sustainability benefits, as we expect this new way of working will reduce the carbon dioxide (CO2) footprint through lower material and energy consumption.”
Individualization and customization are also leading to an increased demand for two-tone schemes. PPG’s breakthrough precision application technology for automotive coatings significantly streamlines the painting of these schemes, producing crisp paint edges without the use of masking and other time-intensive steps currently required to achieve a two-tone finish.
“The conventional process requires that a vehicle be fully painted before paint shop personnel mask off areas that will not receive the second color,” said Reil. “The vehicle must then be run through the paint line or a repair line a second time to apply the contrasting color. In addition to reducing paint shop capacity, this second run can add significant material, labor and energy costs to the total unit cost of the vehicle.”
The precision process uses a specially designed PPG coating as well as innovative application heads that apply the paint directly without overspray. This can reduce paint shop time by approximately 50 minutes per two-tone vehicle. This process also advances customer sustainability goals by reducing CO2 emissions and eliminating energy-intensive air-filtering systems that handle overspray from the paint application process, reducing costs and improving efficiency.
“The process uses a direct printing approach rather than conventional spraying, eliminating overspray and masking,” Reil said. “It allows the application of coatings in an extremely precise manner, giving the ability to combine both sustainability and customization. In the future, complete cars might be painted using precision application technology, offering manufacturers even more options to enhance the appeal of their vehicle models.”
PPG: WE PROTECT AND BEAUTIFY THE WORLD™
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and materials that our customers have trusted for more than 135 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $13.8 billion in 2020. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.
We protect and beautify the world is a trademark and the PPG Logo is a registered trademark of PPG Industries Ohio, Inc.
CATEGORY Automotive OEM Coatings
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005108/en/
Contact information
PPG Media Contacts:
Andrew Wood
Corporate Communications, EMEA
+31 6 5121 6579
awood@ppg.com
Keith Rigby
Automotive OEM Coatings
+1 412-434-1718
krigby@ppg.com
www.ppg.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
